## Mari K Halle

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3669675/publications.pdf

Version: 2024-02-01

28 papers 1,289 citations

623734 14 h-index 27 g-index

28 all docs 28 docs citations

28 times ranked

2857 citing authors

#	Article	IF	CITATIONS
1	Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer. European Radiology, 2022, 32, 6444-6455.	4.5	5
2	High-Grade Cervical Intraepithelial Neoplasia (CIN) Associates with Increased Proliferation and Attenuated Immune Signaling. International Journal of Molecular Sciences, 2022, 23, 373.	4.1	11
3	Fully Automatic Whole-Volume Tumor Segmentation in Cervical Cancer. Cancers, 2022, 14, 2372.	3.7	9
4	Impact of <i>MDM2</i> promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer. Biomarkers, 2021, 26, 302-308.	1.9	4
5	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. British Journal of Cancer, 2021, 124, 1690-1698.	6.4	15
6	Genomic Characterization and Therapeutic Targeting of HPV Undetected Cervical Carcinomas. Cancers, 2021, 13, 4551.	3.7	13
7	Genomic alterations associated with mutational signatures, DNA damage repair and chromatin remodeling pathways in cervical carcinoma. Npj Genomic Medicine, 2021, 6, 82.	3 <b>.</b> 8	9
8	A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival. Cancers, 2021, 13, 5737.	3.7	9
9	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology, 2020, 157, 260-267.	1.4	32
10	Blood Metabolites Associate with Prognosis in Endometrial Cancer. Metabolites, 2019, 9, 302.	2.9	12
11	HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer, 2018, 118, 378-387.	6.4	43
12	Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLoS ONE, 2018, 13, e0206665.	<b>2.</b> 5	11
13	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer, 2017, 17, 97.	2.6	14
14	Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions. Gynecologic Oncology, 2017, 147, 672-677.	1.4	14
15	Clinicopathologic and molecular markers in cervical carcinoma: a prospective cohort study. American Journal of Obstetrics and Gynecology, 2017, 217, 432.e1-432.e17.	1.3	38
16	Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer. Clinical Cancer Research, 2016, 22, 513-523.	7.0	25
17	The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumor Biology, 2016, 37, 10697-10702.	1.8	20
18	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget, 2016, 7, 69844-69856.	1.8	30

#	Article	IF	CITATION
19	Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget, 2015, 6, 1327-1339.	1.8	50
20	Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer. PLoS ONE, 2014, 9, e90141.	2.5	34
21	The evolution and functional divergence of the beta-carotene oxygenase gene family in teleost fishâ€"Exemplified by Atlantic salmon. Gene, 2014, 543, 268-274.	2.2	14
22	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
23	Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix. Pathology Research and Practice, 2014, 210, 774-778.	2.3	0
24	Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. European Journal of Cancer, 2014, 50, 3003-3010.	2.8	73
25	Switch in FOXA1 Status Associates with Endometrial Cancer Progression. PLoS ONE, 2014, 9, e98069.	2.5	22
26	Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget, 2014, 5, 1052-1061.	1.8	35
27	Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas. Histopathology, 2012, 60, 516-519.	2.9	5
28	High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated. PLoS ONE, 2012, 7, e52795.	2.5	34